Recorded May 22, 2023
Each person who is diagnosed with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL / SLL) has a unique set of genetic biomarkers that make their type of the cancer unique to them. Biomarker testing will give you and your healthcare provider a better understanding of what treatments will work best for your disease type (predictive factors) and help to determine how aggressive your risk of the disease might be over time (prognostic factors).
In this session, we will discuss the most common biomarkers found in CLL / SLL, when and how to test for them using CLL Society’s Test Before Treat™ educational resource as a guide, which biomarker test results can change over time, and how some CLL / SLL treatments won’t work as well when certain biomarkers are present. Additionally, we will explore how testing for MRD (measurable residual disease) might serve as a guide for knowing when to start or stop treatment. Don’t miss this informative session on the role of biomarkers in CLL / SLL.
Robyn Brumble, MSN, RN
Director of Scientific Affairs & Research
23-year CLL Patient and Advocate
Director, CLL Society Support Network
Catherine Coombs, MD
Associate Clinical Professor of Medicine
Chao Family Comprehensive Cancer Center
University of California, Irvine
CLL Society Resources
- Download Slides
- CLL Glossary
- Test Before Treat™
- CLL / SLL Patient Education Toolkit
- Normal Lab Values
- More Details on Prognostic and Predictive Tests and When Should I do them for my CLL?
- ASH 2020: Dr. Adrian Wiestner Discusses the Importance of Test Before Treat™ Predictive and Prognostic Biomarker Testing in Patients with CLL
- CLL Support Groups
- Sign up for CLL Society’s This Week email
- Please Consider Donating to CLL Society
This program was made possible by generous donors and grant support from AstraZeneca.